ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,349.25
1.79%
S&P 500
5,749.35
0.07%
Dow Jones
42,417.73
0.58%
US Dollar vs Yen
142.471
-1.82%
Brent Oil
71.73
1.10%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Eiger BioPharmaceuticals Inc (EIGR)

  7. Eiger BioPharmaceuticals Inc (EIGR) ニュース

EIGR

Eiger BioPharmaceuticals (EIGR)

Eiger BioPharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:EIGR
日付受信時刻ニュースソース見出しコード企業名
2024/04/0200 : 12GlobeNewswire Inc.Eiger BioPharmaceuticals Files for Voluntary Chapter 11 ProtectionNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/03/1205 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/2506 : 59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/1907 : 49PR Newswire (US)Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/0821 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/0422 : 45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2024/01/0422 : 00PR Newswire (US)Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock SplitNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/12/1206 : 01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/12/0420 : 01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/12/0206 : 02Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/2420 : 01Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/1406 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/1006 : 27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/1006 : 14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/1006 : 05PR Newswire (US)Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/0310 : 54Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/11/0310 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/10/3105 : 51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/10/2105 : 29Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/2905 : 54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/1306 : 17Dow Jones NewsEiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing TalksNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/1305 : 42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/1305 : 05PR Newswire (US)Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis DeltaNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/0610 : 38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/0610 : 35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/09/0605 : 05PR Newswire (US)Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/08/1519 : 00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/08/1505 : 24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EIGREiger BioPharmaceuticals Inc
2023/08/1505 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
2023/08/1505 : 05PR Newswire (US)Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:EIGREiger BioPharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EIGR

最近閲覧した銘柄

CCOM
SILVER
SILVER
CCOM
US500
US 500
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
NASDAQ
TSLA
Tesla
FX
USDJPY
US Dollar vs Yen
NYSE
AXP
American Express
NYSE
BAC
Bank of America
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
ADDYY
Adidas (QX)
NASDAQ
MSFT
Microsoft
AMEX
XLV
Health Care Select Sector
NYSE
NKE
Nike
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有